Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza's site-specific ADC technologiesReinforces Antharis' and Lonza's position at the forefront...
BAYPORT, Minn., June 15, 2026 /PRNewswire/ -- The Andersen Corporate Foundation has committed over $1.2 million to 86 nonprofit organizations in its spring 2026...
DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Stem Cell Therapy Market is projected to grow from about USD 0.48 billion...
The Project includes a 14-year open-pit silver project delivering strong economics, a rapid 1.9 year payback, and a 63.7-million-ounce payable silver production profile with significant...
DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Companion Diagnostics Market is projected to grow from about USD 6.31 billion in...
Unraveling the Mystery of the Ozone Hole and Advancing Global Environmental GovernanceTAIPEI, June 15, 2026 /PRNewswire/ -- The Tang Prize, one of the world's leading...
STOCKHOLM, June 15, 2026 /PRNewswire/ -- During the period June 8 - June 12, 2026, Telefonaktiebolaget LM Ericsson (publ) ("Ericsson") (LEI code 549300W9JLPW15XIFM52) repurchased...
STOCKHOLM, June 15, 2026 /PRNewswire/ -- During the period June 8 - June 12, 2026, Telefonaktiebolaget LM Ericsson (publ) ("Ericsson") (LEI code 549300W9JLPW15XIFM52) repurchased...
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol...
HOUSTON, June 15, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced positive operational updates offshore Gabon regarding the ongoing drilling program, including impressive initial well results on the Ebouri-5H well and mobilization of the rig to the SEENT platform. Additionally, the Company provided a positive update on the first well completed in the 2026 onshore Egypt drilling program.
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol...